Key Highlights

  • Net loss was USD 110.4 million, compared with USD 90.9 million.
  • Research and development expense was USD 95.6 million.
  • Cash, cash equivalents and marketable securities were USD 1,153.5 million.
  • The NDA for azetukalner in focal seizures was submitted in September 2026.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) reported a third quarter 2026 net loss of USD 110.4 million, compared with USD 90.9 million in the third quarter of 2025. Reported EPS was negative USD 1.11, compared with an estimate of negative USD 1.13. The company reported no revenue.

Research and development expense was USD 95.6 million, compared with USD 77.1 million. For the nine months, the net loss was USD 323.5 million, compared with USD 240.6 million, and Research and Development expense was USD 283.4 million, compared with USD 213.2 million. Cash, cash equivalents and marketable securities were USD 1,153.5 million. Net loss per common share, basic and diluted, was USD 1.11, compared with USD 1.15, and USD 3.38 for the nine months, compared with USD 3.05. General and administrative expenses were USD 24.4 million, compared with USD 19.3 million, and USD 72.2 million for the nine months, compared with USD 57.6 million. Interest income was USD 11.6 million, compared with USD 6.2 million, and total other income was USD 11.5 million, compared with USD 6.1 million. Net loss per common share, basic and diluted, was USD 1.11, compared with USD 1.15, and USD 3.38 for the nine months, compared with USD 3.05. General and administrative expenses were USD 24.4 million, compared with USD 19.3 million, and USD 72.2 million for the nine months, compared with USD 57.6 million. Interest income was USD 11.6 million, compared with USD 6.2 million, and total other income was USD 11.5 million, compared with USD 6.1 million.

Azetukalner Regulatory Progress

The company submitted its New Drug Application for azetukalner, referred to as AZK, in focal seizures to the FDA in September 2026. Management said the package includes two pivotal, randomized, double blind, placebo controlled trials, the Phase IIb X-TOLE study and the Phase III X-TOLE2 study.

Across both studies, all four doses of AZK showed a statistically significant reduction from baseline in monthly seizure frequency compared with placebo. X-TOLE2 reported a 42.7% placebo adjusted median change from baseline, which management described, to its knowledge, as the highest placebo adjusted figure in a pivotal focal seizure study. Management cited a consistent safety profile and more than 1,500 patient years of safety and exposure data across the epilepsy program, along with once daily dosing and the ability to start at a therapeutic dose without titration.

Broader Clinical Programs

The company continues to enroll the Phase III X-TOLE3 and X-ACKT studies of AZK in focal seizures and primary generalized tonic clonic seizures, respectively. It completed enrollment in the Phase III X-NOVA2 study in major depressive disorder with approximately 360 patients, and moved its topline data announcement to December 2026 from the first quarter of 2027.

In pain, the company presented Phase I data for XEN1701, targeting Nav1.7, and XEN1120, targeting Kv7, at the IASP 2026 World Congress on Pain, and said both Assets are moving to Phase II proof of concept studies in acute pain. Management noted its two decade history with Nav1.7, where it identified a loss of function as the cause of congenital indifference to pain.

Pipeline Partnerships

The company also cited a preclinical Nav1.1 program for Dravet syndrome and a partnered Nav1.2 and Nav1.6 program with Neurocrine, with the molecule NBI-921355 advancing through a Phase Ib study, and data cited for 2027. Management referenced its Phase II X-NOVA study, which showed signals of antidepressive effects for Kv7 modulation.

NDA and Clinical Data Timing

Xenon submitted the NDA for azetukalner in focal seizures in September 2026 and held USD 1,153.5 million in cash and marketable securities. The call covered the X-TOLE2 result, timing of new X-NOVA2 data and the stage of the pain program.